Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CTSA | P10619 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29874723 | 0.86 | CYP2C19 (0.42) | HTTLMNAMAPK1RAB9AFFAR1 | |
| SCHEMBL29449427 | 0.86 | CYP2C19 (0.42) | HTTLMNAMAPK1RAB9AFFAR1 | |
| SCHEMBL23362838 | 0.86 | CYP2C19 (0.42) | HTTLMNAMAPK1RAB9AFFAR1 | |
| SCHEMBL20817253 | 0.82 | NPSR1 (0.47) | HTTLMNAMAPK1RAB9APTGS1 | |
| SCHEMBL22457320 | 0.82 | PTGS2 (0.60) | HTTLMNAMAPK1RAB9APTGS1 | |
| SCHEMBL7468522 | 0.81 | KMT2A (0.53) | HTTLMNARAB9APTGS1PTGS2 | |
| SCHEMBL21724123 | 0.81 | ACHE (0.44) | HTTLMNAMAPK1RAB9APTGS1 | |
| SCHEMBL20577005 | 0.81 | TTR (0.48) | HTTLMNAMAPK1PTGS1PTGS2 | |
| Hydrochloric Acid SCHEMBL29072273 | 0.79 | ACHE (0.43) | HTTLMNAMAPK1RAB9APTGS1 | |
| SCHEMBL7466460 | 0.78 | CES2 (0.50) | CYP2C19PKMCA6CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110753691-B | Compounds for therapeutic and/or prophylactic treatment of cancer | 豪夫迈·罗氏有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-11708354-B2 | 2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2023-07-25 | — | — | US | disclosed |
| CN-110325528-B | 2-benzopyrazinyl-N-heteroaryl-2-phenyl-acetamide compounds | 豪夫迈·罗氏有限公司 | 2022-10-11 | — | — | CN | disclosed |
| EP-3558967-B1 | 2-BENZOPYRAZINYL-N-HETEROARYL-2-PHENYL-ACETAMIDE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-03-02 | — | — | EP | disclosed |
| US-11117890-B2 | Substituted isoindole allosteric EGFR inhibitors | HOFFMAN LA-ROCHE INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210070739-A1 | 2-BENZOPYRAZINYL-N-HETEROARYL-2-PHENYL-ACETAMIDE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-10882848-B2 | 2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds | HOFFMANN-LA ROCHE, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| EP-3630754-A1 | COMPOUNDS | H. Hoffnabb-La Roche Ag (CH) | 2020-04-08 | — | — | EP | disclosed |
| US-20200102299-A1 | COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-04-02 | — | — | US | disclosed |
| EP-3558967-A1 | 2-BENZOPYRAZINYL-N-HETEROARYL-2-PHENYL-ACETAMIDE COMPOUNDS | H. Hoffnabb-La Roche Ag (CH) | 2019-10-30 | — | — | EP | disclosed |
| US-20190308955-A1 | 2-BENZOPYRAZINYL-N-HETEROARYL-2-PHENYL-ACETAMIDE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2019-10-10 | — | — | US | disclosed |
| WO-2018220149-A1 | COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-12-06 | — | — | WO | disclosed |
| WO-2018115218-A1 | 2-BENZOPYRAZINYL-N-HETEROARYL-2-PHENYL-ACETAMIDE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117890-B2 | Substituted isoindole allosteric EGFR inhibitors | EGFR, ERBB2, ERBB3 | HTT 2694/4885LMNA 4878/4885MAPK1 513/4885 |
| US-11708354-B2 | 2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds | EGFR, ERBB2, ERBB3 | HTT 1303/4885LMNA 4285/4885MAPK1 1096/4885 |
| US-10882848-B2 | 2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds | EGFR, ERBB2, ERBB3 | HTT 1303/4885LMNA 4285/4885MAPK1 1096/4885 |
| US-20210070739-A1 | 2-BENZOPYRAZINYL-N-HETEROARYL-2-PHENYL-ACETAMIDE COMPOUNDS | EGFR, ERBB2, ERBB3 | HTT 1303/4885LMNA 4285/4885MAPK1 1096/4885 |
| US-20190308955-A1 | 2-BENZOPYRAZINYL-N-HETEROARYL-2-PHENYL-ACETAMIDE COMPOUNDS | EGFR, ERBB2, ERBB3 | HTT 1303/4885LMNA 4285/4885MAPK1 1096/4885 |
| US-20200102299-A1 | COMPOUNDS | EGFR, ERBB2, ERBB3 | HTT 2602/4885LMNA 1605/4885MAPK1 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.